Document is current

Article History

Received: 21 March 2022

Accepted: 24 April 2022

First Online: 10 May 2022

Declarations

:

: Not applicable.

: Not applicable.

: Paolo A. Ascierto (PAA): <i>Employment or Leadership Position</i>: None; ​ <i>Consultant/Advisory Role</i>: Bristol-Meyers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Merck Serono, Pierre-Fabre, AstraZeneca, Sun Pharma, Sanofi, Idera, Sandoz, Immunocore, 4SC, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, OncoSec, Nouscom, Lunaphore, Seagen, iTeos, Medicenna; <i>Stock Ownership</i>: None;​ <i>Research Funding</i>: Bristol-Meyers Squibb, Roche-Genentech, Pfizer, Sanofi​; <i>Expert Testimony</i>: None​; <i>Other Remuneration</i>: None​Allison Betof Warner (ABW): <i>Research Funding (Institutional):</i> Iovance Biotherapeutics, Leap Therapeutics, Daiichi Sankyo; <i>Consulting</i>: Iovance Biotherapeutics, BluePath Solutions, Nanobiotix, Novartis, Pfizer; <i>Honoraria</i>: Shanghai Jo’Ann Medical Technology.Christian Blank (CB): <i>Advisory role</i>: BMS, MSD, Roche, Novartis, GSK, AZ, Pfizer, Lilly, GenMab, Pierre Fabre, Third Rock Ventures; <i>Research funding</i>: BMS, Novartis, NanoString, 4SC; S<i>tockownership</i>: co-founder Immagene BV.Sandra Demaria (SD): has received compensation for consultant/advisory services from Lytix Biopharma, EMD Serono, Ono Pharmaceutical, and Genentech, and research support from Lytix Biopharma, Nanobiotix and Boehringer-Ingelheim.Jeffrey E. Gershenwald (JEG): Consultant and/or advisory role: Merck, Regeneron, Syndax.Nikhil I. Khushalani (NIK): is a compensated consultant for BMS, Jounce, Iovance, Merck, Immunocore, Regeneron, Sanofi, Novartis, Incyte, and AstraZeneca (Incyte, AZ-Data Safety Monitoring Committee); stock ownership in Bellicum, Asensus Surgical, Amarin; research support (all to institution) from BMS, Merck, Celgene, Novartis, GSK, HUYA, Amgen, Regeneron, Replimmune and Genentech.Georgina V. Long (GVL): Consultant advisor for Agenus Inc, Amgen Inc, Array Biopharma Inc, Boehringer Ingelheim International GmbH, Bristol Myers Squibb, Evaxion Biotech A/S, Hexal AG (Sandoz Company), Highlight Therapeutics S.L., Merck Sharpe & Dohme (Australia) Pty Limited, Novartis Pharma AG, OncoSec Medical Australia, Pierre Fabre, Provectus, Qbiotics Group Limited, Regeneron Pharmaceuticals Inc.Jason J. Luke (JJL): <i>Data and Safety Monitoring Board</i>: TTC Oncology; <i>Scientific Advisory Board</i>: 7 Hills, Actym, Alphamab Oncology, Mavu (now part of AbbVie), Pyxis, Springbank, Tempest; <i>Consultancy</i>: Abbvie, Akrevia, Algios, Array, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Compugen, Eisai, EMD Serono, Ideaya, Immunocore, Incyte, Janssen, Leap, Merck, Mersana, Novartis, RefleXion, Silicon, Tesaro, Vividion; <i>Research Support</i>: (all to institution for clinical trials unless noted): AbbVie, Agios (IIT), Array (IIT), Astellas, Boston Biomedical, Bristol-Myers Squibb, CheckMate (SRA), Compugen, Corvus, EMD Serono, Evelo (SRA), Five Prime, FLX Bio, Genentech, Immatics, Immunocore, Incyte, Leap, MedImmune, Macrogenics, Necktar, Novartis, Palleon (SRA), Merck, Springbank, Tesaro, Tizona, Xencor; <i>Travel</i>: Akrevia, AstraZeneca, Bayer, Bristol-Myers Squibb, EMD Serono, Immunocore, Incyte, Janssen, Merck, Mersana, Novartis, RefleXion; <i>Patents</i>: (both provisional) Serial #15/612,657 (Cancer Immunotherapy), PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof).Janice M. Mehnert (JMM): Advisory board: Novartis; Research funding: Novartis, Merck, BMS; Consultant: Merck, AD board: BMS.Caroline Robert (CR): Advisory for Roche, BMS, MSD, Novartis, Merck, Pierre Fabre, Sanofi, AstraZeneca; Scientific co-founder of RiboNexus.Piotr Rutkowski (PR): has received honoraria for lectures and Advisory Boards from BMS, MSD, Novartis, Pierre Fabre, Sanofi, Merck, Philogen and Blueprint Medicines outside of the scope of this manuscript.Hussein A. Tawbi (HAT): <i>Consulting or Advisory Role</i>: Novartis, Bristol-Myers Squibb, Genentech/Roche, Merck, Array BioPharma, Eisai, Iovance Biotherapeutics, Karyopharm Therapeutics, Boxer Capital, Jazz Pharmaceuticals, Pfizer; <i>Research Funding</i>: Bristol-Myers Squibb, Novartis, Merck, GlaxoSmithKline, Genentech/Roche, Celgene, Dragonfly Therapeutics, RAPT Therapeutics.Corrado Caracò (CC): no conflict to disclose.Iman Osman (IO): no conflict to disclose.Igor Puzanov (IP): <i>Consulting/Honoraria</i>: Nektar, Amgen, Roche, Oncorus​; <i>Advisory Board</i>: Bristol-Myers Squibb, Nektar​; <i>Institutional Clinical Trial Support</i>: Nektar, Idera, Oncosec, Amgen, Immunocore, Dynavax, Rubius, SQZ, ADC​; <i>DSMC</i>: Nouscom​; <i>Stock</i>: Celldex.